ABVC Biopharma (ABVC) Osake Kurssi

American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 34 full-time employees. The company went IPO on 2004-11-09. The firm is a biotechnology company focused on the development of drugs and medical devices. The company is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to enhance the development of pre-existing pharmaceutical products for the treatment of various cancer indications and other diseases; prospectively identify patients that may respond to such pharmaceutical products, and commercialize such pharmaceutical products for license in various markets. The firm's operation is the research and development of five compound licensed to the Company by BioLite Inc. The compounds include ABV-1501, ABV-1502, ABV-1503, ABV-1504 and ABV-1505. As of September 30, 2016, the Company had not generated any revenues from its operations.